Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15128998 | 0.88 | CNR2 (0.60) | CNR2MEN1KMT2APTGER1CDK2 | |
| SCHEMBL15129078 | 0.88 | CNR2 (0.60) | CNR2MEN1KMT2APTGER1CDK2 | |
| SCHEMBL15129404 | 0.86 | CNR2 (0.58) | CNR2MEN1KMT2APTGER1CDK2 | |
| SCHEMBL12420758 | 0.86 | CNR2 (0.60) | CNR2PTGER1CDK2CCNA2CCNA1 | |
| SCHEMBL11664017 | 0.81 | CYP1A2 (0.58) | CNR2MEN1KMT2APTGER1CYP1A2 | |
| SCHEMBL15129281 | 0.80 | CNR2 (0.54) | CNR2PTGER1CDK2CCNA2CCNA1 | |
| SCHEMBL15134605 | 0.80 | CNR2 (0.54) | CNR2PTGER1CDK2CCNA2CCNA1 | |
| SCHEMBL12478630 | 0.79 | CNR2 (0.61) | CNR2PTGER1FFAR4 | |
| SCHEMBL15129249 | 0.78 | CNR2 (0.52) | CNR2PTGER1CDK2CCNA2CCNA1 | |
| SCHEMBL15129007 | 0.75 | CNR2 (0.52) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447078-B2 | Substituted heterocyclic compounds for disease treatment | ACUCELA INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447078-B2 | Substituted heterocyclic compounds for disease treatment | ACUCELA INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013109991-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | CLN6, ALDH1A2, PDE6D | CNR2 1376/4885MEN1 3323/4885KMT2A 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.